Showing results 60 to 79 of 112
< previous
next >
| Issue Date | Title | Author(s) |
| 2016-01-01 | The need to research refractory breathlessness | Currow, DC; Abernethy, AP; Allcroft, P; Banzett, RB; Bausewein, C; Booth, S; Carrieri-Kohlman, V; Davidson, P; Disler, R; Donesky, DA; Dudgeon, D; Ekstrom, M; Farquhar, M; Higginson, I; Janssen, D; Jensen, D; Jolley, C; Krajnik, M; Laveneziana, P; McDonald, C; Maddocks, M; Morelot-Panzini, C; Moxham, J; Mularski, RA; Noble, S; O'Donnell, D; Parshall, MB; Pattinson, K; Phillips, J; Ross, J; Schwartzstein, RM; Similowski, T; Simon, ST; Smith, T; Wells, A; Yates, P; Yorke, J; Johnson, MJ |
| 2020 | No excess harms from sustained-release morphine: a randomised placebo-controlled trial in chronic breathlessness. | Johnson, MJ; Sbizzera, I; Fairhurst, C; Fazekas, B; Agar, M; Ekstrom, M; Currow, DC |
| 2021-07-02 | Non-medical devices for chronic breathlessness: use, barriers and facilitators for patients, carers and clinicians - a scoping review | Prihartadi, AS; Licastro, GI; Pearson, M; Johnson, MJ; Luckett, T; Swan, F |
| 2017-04-03 | Non-opioid medications for the relief of chronic breathlessness: current evidence | Barbetta, C; Currow, DC; Johnson, MJ |
| 2017-03-01 | O-3 Opioids, benzodiazepines, anti-cholinergic load and clinical outcomes in patients with advanced cancer | Boland, JW; Allgar, V; Boland, EG; Oviasu, O; Agar, M; Currow, DC; Johnson, MJ |
| 2020-07-16 | Observational studies and "the eye of the beholder". | Johnson, MJ; Ekström, M; Currow, DC |
| 2011-09-01 | Once-daily opioids for chronic dyspnea: A dose increment and pharmacovigilance study | Currow, DC; McDonald, C; Oaten, S; Kenny, B; Allcroft, P; Frith, P; Briffa, M; Johnson, MJ; Abernethy, AP |
| 2018-01-01 | One evidence base; three stories: do opioids relieve chronic breathlessness? | Ekström, M; Bajwah, S; Bland, JM; Currow, DC; Hussain, J; Johnson, MJ |
| 2020-07-03 | Opioids for breathlessness: a narrative review. | Johnson, MJ; Currow, DC |
| 2013-09-01 | Opioids for chronic refractory breathlessness: Patient predictors of beneficial response | Johnson, MJ; Bland, JM; Oxberry, SG; Abernethy, AP; Currow, DC |
| 2016-04-01 | Opioids in chronic obstructive pulmonary disease: The whole picture using all available evidence | Currow, DC; Ekström, M; Johnson, MJ |
| 2016-03-01 | Opioids, Exertion, and Dyspnea: A Review of the Evidence | Johnson, MJ; Hui, D; Currow, DC |
| 2019-12-01 | Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo-controlled trial | Johnson, MJ; Cockayne, S; Currow, DC; Bell, K; Hicks, K; Fairhurst, C; Gabe, R; Torgerson, D; Jefferson, L; Oxberry, S; Ghosh, J; Hogg, KJ; Murphy, J; Allgar, V; Cleland, JGF; Clark, AL |
| 2015-01-01 | Outcome measurement of refractory breathlessness: Endpoints and important differences | Ekstrom, M; Currow, DC; Johnson, MJ |
| 2021-12 | Outcomes and measures of delirium interventional studies in palliative care to inform a core outcome set: A systematic review. | Agar, MR; Siddiqi, N; Hosie, A; Boland, JW; Johnson, MJ; Featherstone, I; Lawlor, PG; Bush, SH; Page, V; Amgarth-Duff, I; Garcia, M; Disalvo, D; Rose, L; Del-COrS Group, |
| 2017-09-01 | Overdosing on immediate-release morphine solution has predictable adverse effects | Currow, DC; Ekström, M; Johnson, MJ |
| 2020-01-01 | Palliative Care for people living with heart failure - European Association for Palliative Care Task Force expert position statement. | Sobanski, PZ; Alt-Epping, B; Currow, DC; Goodlin, SJ; Grodzicki, T; Hogg, K; Janssen, DJA; Johnson, MJ; Krajnik, M; Leget, C; Martínez-Sellés, M; Moroni, M; Mueller, PS; Ryder, M; Simon, ST; Stowe, E; Larkin, PJ |
| 2021-12 | Performance status and trial site-level factors are associated with missing data in palliative care trials: An individual participant-level data analysis of 10 phase 3 trials. | Hussain, JA; White, IR; Johnson, MJ; Bland, M; Currow, DC |
| 2018-01-01 | Pharmacovigilance in Hospice/Palliative Care: Net Effect of Haloperidol for Nausea or Vomiting | Digges, M; Hussein, A; Wilcock, A; Crawford, GB; Boland, JW; Agar, MR; Sinnarajah, A; Currow, DC; Johnson, MJ |
| 2023 | Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial). | Sousa, MS; Martin, P; Johnson, MJ; Lind, M; Maddocks, M; Bullock, A; Agar, M; Chang, S; Kochovska, S; Kinchin, I; Morgan, D; Fazekas, B; Razmovski-Naumovski, V; Lee, JT; Itchins, M; Bray, V; Currow, DC; Matsubara, J |
